Lokivetmab
Lokivetmab
Lokivetmab (pronounced loh-kee-vet-mab) is a monoclonal antibody used in veterinary medicine. It is marketed under the trade name Cytopoint, and is used to treat canine atopic dermatitis.
Etymology
The name "Lokivetmab" is derived from the Greek words "loki", meaning "location", "vet", an abbreviation for "veterinary", and "mab", an abbreviation for "monoclonal antibody". This reflects the drug's specific use in veterinary medicine and its nature as a monoclonal antibody.
Usage
Lokivetmab is used to treat canine atopic dermatitis, a common allergic skin disease in dogs. It works by targeting and neutralizing interleukin-31 (IL-31), a protein that sends itch signals to the brain. This helps to reduce itching and inflammation in dogs suffering from atopic dermatitis.
Related Terms
- Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Canine atopic dermatitis: A common allergic skin disease in dogs.
- Interleukin-31 (IL-31): A protein that sends itch signals to the brain.
- Cytopoint: The trade name under which Lokivetmab is marketed.
See Also
External links
- Medical encyclopedia article on Lokivetmab
- Wikipedia's article - Lokivetmab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski